Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …

Background—Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF)
patients unsuitable for warfarin by 63% but does not increase major bleeding. We sought to …

Introduction Atrial fibrillation (AF), one of the major risk factors for stroke, imposing a
substantial burden to the Swedish health care system. Apixaban has demonstrated …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

ABSTRACT BACKGROUND: Apixaban, an oral anticoagulant for stroke and systemic
embolism prevention in non-valvular atrial fibrillation (NVAF), was superior to warfarin in …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …

Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …